Sodium-glucose cotransporter 2 (SGLT-2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists were originally developed for the control of hyperglycaemia in patients with DM type 2. Here, SLC5A2 is linked to Hyperglycemia.